Evaluating how vancomycin affects outcomes in C. difficile infections
Vancomycin Susceptibility Measures to Evaluate C. difficile infection Outcomes
['FUNDING_R03'] · UNIVERSITY OF HOUSTON · NIH-11015077
This study is looking at how well the antibiotic vancomycin works to treat Clostridioides difficile infections, aiming to find the best doses that can help patients feel better and get rid of the bacteria.
Quick facts
| Phase | ['FUNDING_R03'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF HOUSTON (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11015077 on ClinicalTrials.gov |
What this research studies
This research investigates the effectiveness of vancomycin, an antibiotic, in treating Clostridioides difficile infections (CDI). It aims to establish reliable measures of antibiotic susceptibility that can predict patient outcomes, focusing on whether certain concentrations of vancomycin can effectively eliminate the bacteria. By analyzing the relationship between vancomycin concentrations and clinical outcomes, the research seeks to improve treatment strategies for patients suffering from CDI. The study will utilize microbiologic assays to assess the bactericidal and inhibitory effects of vancomycin on C. difficile isolates.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Clostridioides difficile infections who are undergoing treatment with vancomycin.
Not a fit: Patients who do not have Clostridioides difficile infections or those who are not being treated with vancomycin may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment protocols for patients with C. difficile infections, potentially reducing treatment failures.
How similar studies have performed: Previous research has shown that antibiotic susceptibility testing can improve treatment outcomes in various bacterial infections, suggesting potential success for this approach in CDI.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF HOUSTON — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GAREY, KEVIN W — UNIVERSITY OF HOUSTON
- Study coordinator: GAREY, KEVIN W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.